Latest News in Cancer
Stay updated with the most recent articles and resources.
Main Topics
Liver Transplantation for Alcohol-Related Cirrhosis: Eligibility and Outcomes
Liver transplant is a critical treatment for cirrhosis due to alcoholism, providing an opportunity for recuperation for end-stage liver disease patients. Stringent eligibility criteria, such...
The Role of Living Donor Liver Transplants in Addressing Organ Shortages
Living donor liver transplant (LDLT) is vital in the treatment of organ deficits, with improved success rates and shorter waiting periods. With increased cases of...
Understanding Post-Liver Transplant Medications: A Comprehensive Guide
Following a liver transplant, it is important to take lifelong medicines to avoid organ rejection and control resultant conditions. This manual deals with important immunosuppressive...
Ensartinib is approved by the USFDA for ALK-positive locally advanced or metastatic non-small cell lung cancer
On December 18, 2024, the Food and Drug Administration sanctioned ensartinib (Ensacove, Xcovery Holdings, Inc.) for adult patients with anaplastic lymphoma kinase (ALK)-positive locally...
Cosibelimab-ipdl is approved by the USFDA for metastatic or locally advanced cutaneous squamous cell carcinoma
The FDA has approved cosibelimab (iPDL1) for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC). This PD-L1 inhibitor demonstrated significant efficacy in clinical trials,...
Durvalumab is approved by the USFDA for limited-stage small cell lung cancer
The FDA has approved durvalumab (Imfinzi) for limited-stage small cell lung cancer (LS-SCLC), marking a significant advancement in treatment. This approval is based on clinical...
Unlocking the Potential of Astraeus asiaticus: A Natural Anticancer and Antioxidant Agent
Astraeus asiaticus, an edible wild mushroom, has shown remarkable anticancer and antioxidant potential. Researchers identified key bioactive compounds that inhibit cervical, breast, and lung cancer...
Zenocutuzumab-zbco is approved by the USFDA for non-small cell lung cancer and pancreatic adenocarcinoma
The FDA has granted accelerated approval to Zenocutuzumab for non-small cell lung cancer and pancreatic cancer with NRG1 gene fusion. This bispecific antibody targets HER2...
Zanidatamab-hrii is approved by the USFDA for previously treated unresectable or metastatic HER2-positive biliary tract cancer
The FDA has granted accelerated approval to Zanidatamab for previously treated, unresectable, or metastatic HER2-positive cancers. This bispecific antibody targets HER2 with enhanced precision, offering...
Revumenib is approved by the USFDA for relapsed or refractory acute leukemia with a KMT2A translocation
The FDA has approved Revumenib for relapsed or refractory acute leukemia with KMT2A translocation. This breakthrough treatment offers new hope for patients with limited options....
Enhancing Cancer Outcomes: The Critical Role of Early CAR T-Cell Therapy
CAR T-cell therapy is revolutionizing cancer treatment, offering a highly personalized approach to fighting hematologic malignancies. Early intervention with this groundbreaking therapy can significantly improve...
Obecabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia
On November 8, 2024, the Food and Drug Administration sanctioned obecabtagene autoleucel (Aucatzyl, Autolus Inc.), a CD19-targeted genetically engineered autologous CAR T cell therapy, for...
Need help? Our team is ready to assist you.
We wish a speedy recovery for your loved ones.